Does a two-dose HPV vaccination schedule provide non-inferior efficacy or effectiveness against HPV infection and associated clinical outcomes and non-inferior immune response (immunogenicity) compared to a three-dose schedule for individuals aged 15 years and older?
Authors
Clark, HelenReynolds, Julia
Leen, Brendan
Walsh, Gillian
Brennan, Margaret
Ó Broinn, Cathal
Jessop, Lucy
Kelleher, Kevin
Ward, Mary
Affiliation
Health Library Ireland (HLI)Issue Date
2022-07-15Keywords
HUMAN PAPILLOMAVIRUSVACCINATION
IMMUNISATION
IMMUNE SYSTEM
CANCER, CERVICAL